Veracyte, Inc. revenue by segment VCYT

Annual Quarterly

Veracyte, Inc. splits its revenue into 12 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Testing at $493.2 million, 95% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	582	517	446	361	297	220	117	120	92	72	65
Testing	—	493 +17.7% share 95.4%	419 +28.3% share 94.0%	327 +30.3% share 90.4%	251 +33.1% share 84.5%	188 +84.5% share 85.7%	102 -5.0% share 86.8%	107 +17.9% share 89.2%	91 +26.6% share 99.0%	72 share 100.0%	—
Product	—	14 +5.0% share 2.8%	14 -12.4% share 3.1%	16 +23.4% share 4.3%	13 share 4.3%	—	—	1 share 0.8%	—	—	—
Biopharmaceutical And Other	—	—	13 -30.5% share 3.0%	19 -43.3% share 5.2%	33 share 11.2%	—	—	—	—	—	—
Biopharmaceutical And Other Development Services	—	—	—	—	—	10 share 4.7%	—	1 share 0.8%	—	—	—
Testing Other	—	6 -47.5% share 1.2%	12 +51.3% share 2.6%	8 +151.6% share 2.2%	3 share 1.0%	—	—	—	—	—	—
Biopharmaceutical And Other Collaboration Milestones	—	—	—	—	—	—	—	4 share 3.3%	—	—	—
Biopharmaceutical And Other Contract Manufacturing And Testing	—	3 -47.9% share 0.6%	6 +19.0% share 1.3%	5 -28.1% share 1.4%	7 share 2.4%	—	—	—	—	—	—
Biopharmaceutical And Other Provision Of Data	—	—	—	—	—	2 share 0.9%	—	7 share 5.9%	—	—	—
Biopharmaceutical And Other Development Rights	—	—	—	—	—	—	1 share 0.9%	—	—	—	—
Biopharmaceutical	—	—	—	—	—	—	—	—	1 share 1.0%	—	—
Biopharmaceutical And Other Contract Testing	—	—	—	—	—	0 share 0.2%	—	—	—	—	—
Biopharmaceutical And Other Milestones Excluding Collaboration	—	—	—	—	—	0 -65.0% share 0.2%	1 share 0.9%	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Services-Medical Laboratories (SIC 8071)
Listed as: VCYT (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: South San Francisco, CA
SEC filer status: Large accelerated filer
SEC CIK: 1384101
Former names: CALDEROME INC (until Feb 27, 2008)

Other Services-Medical Laboratories companies

All 29 Services-Medical Laboratories companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.